New Twists on Old Torts: Biosimilars/Biologics Webinar Series
Mintz Levin is proud to host a webinar series covering the Intellectual Property, Health Regulatory, FDA, Patent Litigation, Transactional, and Products Liability issues facing researchers, manufacturers, and distributors of biologics-based therapeutics. Mintz Levin is one of the few law firms with the comprehensive cross-practice knowledge and experience to handle all of these issues, and we look forward to introducing that capability to you and discussing the rapidly evolving biologics/biosimilars landscape.
In this latest addition to our series, we'll discuss how product liability suits impact biosimilars. Those attending will come away with an understanding of the litigation issues that manufacturers of biosimilars will be facing and how to best prepare for them. How will biosimilars fare under the current law?
- In The Weeds: Key Intellectual Property Takeaways For The Cannabis Industry
- USPTO October 2019 Patent Eligibility Guidance Update Includes New Example for Products of Nature
- Manufacturers are Not Immune to Claims that their Inventions are Patent-Ineligible
- Focus On Innovation Centers: Due Diligence For Collaborative Ventures